Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The relationship of the effective dose and safety of cinacalcet hydrochloride and etelcalcetide hydrochloride in the Japanese patients with secondary hyperparathyroidism receiving hemodialysis, when switching cinacalcet hydrochloride to etelcalcetide hydrochloride.

Trial Profile

The relationship of the effective dose and safety of cinacalcet hydrochloride and etelcalcetide hydrochloride in the Japanese patients with secondary hyperparathyroidism receiving hemodialysis, when switching cinacalcet hydrochloride to etelcalcetide hydrochloride.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Etelcalcetide (Primary) ; Cinacalcet
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 21 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top